Literature DB >> 19139735

An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality.

F L Dignan1, S O Evans, M E Ethell, B E Shaw, F E Davies, C E Dearden, J G Treleaven, U B G Riley, G J Morgan, M N Potter.   

Abstract

Empirical antifungal therapy is frequently used in allogeneic transplant patients who have persistent febrile neutropenia and can be associated with high cost, toxicity and breakthrough infections. There are limited reports of strategies for early diagnosis of invasive fungal infection (IFI) and, to our knowledge, no reports of treatment strategies based only on high-resolution computerized tomography (HRCT) scans. We used an early treatment strategy for IFI in 99 consecutive patients undergoing allogeneic transplantation. Patients received caspofungin if they had antibiotic-resistant neutropenic fever for more than 72 h and a positive HRCT scan. Fifty-three of 99 patients (54%) had antibiotic-resistant neutropenic fever at 72 h and would have received parenteral antifungal treatment if an empirical approach had been used. The HRCT-based strategy reduced the use of parenteral antifungal agents to 17/99 patients (17%), a 68% reduction. No subsequent diagnoses of IFI occurred within 100 days in patients with a negative HRCT. Only one patient died from IFI within 100 days. These data suggest that this non-empirical strategy may be feasible and that caspofungin may be effective in this setting. A randomized controlled trial is warranted to further assess these results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139735     DOI: 10.1038/bmt.2008.427

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  The role of antifungal treatment in hematology.

Authors:  Johan A Maertens; Marcio Nucci; J Peter Donnelly
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

2.  Pathogen identification by nuclear imaging--almost there?

Authors:  Samir G Agrawal; Stephen J Mather
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07       Impact factor: 9.236

3.  Pulmonary invasive fungal disease and bacterial pneumonia: a comparative study with high-resolution CT.

Authors:  Wei Chen; Xuanqi Xiong; Bin Xie; Yuan Ou; Wenjing Hou; Mingshan Du; Yongling Chen; Kang Chen; Jing Li; Li Pei; Gang Fu; Dingyuan Liu; Ying Huang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

4.  The management of febrile neutropenia in the posaconazole era: a new challenge?

Authors:  Livio Pagano; Morena Caira; Manuel Cuenca-Estrella
Journal:  Haematologica       Date:  2012-07       Impact factor: 9.941

5.  The Importance of Previous CT Scans in the Diagnosis of Invasive Pulmonary Aspergillosis.

Authors:  Dries Hendrik Deeren
Journal:  Ther Adv Hematol       Date:  2011-04

6.  Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach.

Authors:  Manuela Aguilar-Guisado; Almudena Martín-Peña; Ildefonso Espigado; Maite Ruiz Pérez de Pipaon; José Falantes; Fátima de la Cruz; José M Cisneros
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 7.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

8.  Use of antifungal drugs in hematology.

Authors:  Marcio Nucci
Journal:  Rev Bras Hematol Hemoter       Date:  2012

9.  Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections.

Authors:  C Orla Morrissey
Journal:  Curr Fungal Infect Rep       Date:  2013-01-11

10.  Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Authors:  Michaela Döring; Ulrike Hartmann; Annika Erbacher; Peter Lang; Rupert Handgretinger; Ingo Müller
Journal:  BMC Infect Dis       Date:  2012-07-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.